Ectopic Pregnancy (Unruptured)MANAGEMENT

OBSTETRIC PRESENTATIONS · 12 SECTIONS

⚲

620 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Chorioamnionitis Eclampsia Ectopic Pregnancy (Ruptured)Ectopic Pregnancy (Unruptured)HELLP Syndrome Hyperemesis gravidarum Peripartum cardiomyopathy Placenta previa Placental abruption Postpartum Endometritis Postpartum hemorrhage Postpartum infection Preeclampsia Preeclampsia-eclampsia Preterm labor Sepsis in pregnancy Septic abortion Shoulder dystocia Spontaneous Abortion (Incomplete)Spontaneous Abortion (Missed)Spontaneous Abortion (Threatened)Threatened-inevitable-incomplete abortion Umbilical cord prolapse

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp40

Immediate priorities

›Hemodynamic status

›Tachycardia or hypotension suggests ruptured ectopic

›HR >100 bpm as alarm threshold

›SBP <90 mmHg as shock indicator

›Diaphoresis, pallor, syncope as rupture signs

›IV access x2 large bore immediately

›Type and crossmatch on arrival

›If hemodynamically unstable, presumptive ruptured ectopic until proven otherwise

›Surgical consultation emergent

›Do not delay OR for imaging

Resuscitation triggers

›Ruptured ectopic resuscitation

›1 L crystalloid IV bolus for hypotension

›Permissive hypotension SBP 80-90 mmHg pending OR

›Avoid over-resuscitation diluting coagulation factors

›Activate massive transfusion protocol if refractory

›PRBC:FFP:Plt 1:1:1 ratio

›OB/GYN and OR team activation simultaneous

›Rh blood type priority for Rh immunoglobulin

›Rh negative patients at risk for sensitization

›Administer 300 mcg Rh immunoglobulin IM

Monitoring and targets

›Monitoring bundle

›Continuous cardiac monitoring

›Tachycardia as ongoing hemorrhage marker

›Trending HR for response to resuscitation

›Continuous pulse oximetry

02History/hx65

Presentation pattern

›Classic triad

›Amenorrhea

›Symptoms typically at 5-8 weeks gestational age

›LMP and cycle regularity assessment

›Vaginal bleeding

›Typically intermittent, light, bright or dark red

›Rarely exceeds normal menstrual flow

›Pelvic or lower abdominal pain

›Unilateral or bilateral, crampy, dull, or sharp

›Ranges from mild to debilitating

›Fewer than half of patients present with all three classic features

Alarm symptoms

›High-risk features

›Shoulder tip pain

›Diaphragmatic irritation from hemoperitoneum

›Late and ominous sign suggesting rupture

›Syncope or near-syncope

›Significant hemorrhage indicator

›Hemodynamic compromise risk

›Sudden severe generalized abdominal pain

›May paradoxically improve briefly after rupture

›Peritoneal blood irritation pattern

›Passage of tissue

›Does not distinguish miscarriage from ectopic

›May represent decidual cast from ectopic

Risk factors

›High-risk history

03Physical Exam/exam46

Vitals and hemodynamic assessment

›Stability snapshot

›Heart rate

›>100 bpm as tachycardia threshold

›Orthostatic tachycardia as early volume depletion sign

›Blood pressure

›SBP <90 mmHg as shock indicator

›Postural hypotension as early sign

›Respiratory rate

›Elevated with significant hemorrhage

›Peritoneal irritation splinting

›Temperature

›Low-grade fever possible with hemoperitoneum

›High fever suggests alternative infectious diagnosis

Abdominal exam

›Abdominal findings

›Tenderness

›Unilateral lower quadrant most common

›Diffuse guarding suggests free hemoperitoneum

›Peritoneal signs

›Rebound tenderness

›Voluntary and involuntary guarding

›Rigid abdomen

›Late sign suggesting significant hemoperitoneum

›Emergent surgical consultation trigger

Pelvic exam

›Gynecologic findings

›Cervical os

04Differential Diagnosis/ddx40

Life-threatening diagnoses

›Immediate threats

›Ruptured ectopic pregnancy

›ICD-10 O00.10

›Free hemoperitoneum, hemodynamic instability

›Ruptured hemorrhagic ovarian cyst

›ICD-10 N83.0

›Negative pregnancy test differentiates

›Ovarian torsion

›ICD-10 N83.5

›Absent or diminished ovarian blood flow on Doppler

›Other significant diagnoses

›Appendicitis

›ICD-10 K35.80

›Most common abdominal surgical emergency with right-sided pain overlap

›Septic abortion

›Fever and uterine tenderness

›Positive pregnancy test with open cervical os

Common mimics

›Pregnancy-related mimics

›Threatened or incomplete miscarriage

›ICD-10 O20.0 and O03

›Most common mimic; open os with tissue suggests miscarriage

›Normal early IUP with physiologic bleeding

›Implantation bleeding at expected period time

›Beta-hCG rising appropriately >53% per 48 hours

›Gestational trophoblastic disease

›Markedly elevated beta-hCG

05Laboratory Tests/lt40

Beta-hCG interpretation

›Quantitative serum beta-hCG

›Essential first-line test in all reproductive-age females with abdominal or pelvic pain

›Point-of-care urine hCG positive >20-25 mIU/mL

›Quantitative serum level guides further management

›Discriminatory zone

›IUP should be visible on TVUS when beta-hCG >3,000-3,500 mIU/mL

›Conservative threshold to avoid interrupting viable IUP

›Serial beta-hCG monitoring

›Normal IUP: rises >=49-53% every 48 hours

›Rise <49% or abnormal decline suggests abnormal pregnancy

›Cornerstone of diagnosis when TVUS nondiagnostic

›Beta-hCG >3,500 mIU/mL with no IUP on TVUS highly suspicious for ectopic

Hematology and blood type

›Essential blood tests

›Complete blood count

›Baseline hemoglobin for hemorrhage assessment

›Low Hgb may suggest occult hemorrhage

›Leukocytosis may indicate peritoneal irritation or infection

›Blood type and Rh status

›Mandatory for all pregnant patients

›Rh-negative patients require Rh immunoglobulin 300 mcg IM

›Type and crossmatch

›If hemodynamic instability present

›Prepare for emergency surgical blood loss

Metabolic and organ function labs

›Pre-treatment labs for methotrexate eligibility

›Basic metabolic panel and creatinine

06Diagnostic Tests/dt88

Scoring Systems

›Risk stratification tools for ectopic pregnancy

›M4 score (beta-hCG, progesterone, uterine characteristics, age)

›Multivariate prediction model for ectopic vs IUP

›Sensitivity approximately 70-80% depending on study

›Used as adjunct not replacement for clinical judgment

›Pregnancy of unknown location (PUL) management algorithm

›Classify as PUL when TVUS nondiagnostic with positive beta-hCG

›Serial beta-hCG 48h intervals until localized

›ACEP Level B recommendation for serial beta-hCG in PUL

›Beta-hCG ratio strategy

›Day 0 to Day 2 ratio <0.87 associated with failing pregnancy

›High-sensitivity for prediction of ectopic in selected series

›Not validated for standalone decision-making

›Limitations of scoring

›No score replaces clinical assessment with TVUS

›Heterotopic pregnancy may score as IUP

›Dynamic monitoring supersedes single-point prediction

MRI

›MRI pelvis role in ectopic pregnancy

›Primary indications

›Non-tubal ectopic pregnancy localization

›Cornual, cervical, or caesarean scar ectopic

›Ovarian or abdominal ectopic location

›Inconclusive TVUS with diagnostic uncertainty

›Complex adnexal mass characterization

›Retroperitoneal extension assessment

›MRI characteristics of ectopic pregnancy

›Gestational sac with trophoblastic ring on T2

›High signal decidual reaction

›Low signal fibromuscular tubal wall

›Hemorrhagic content T1 hyperintense

›Distinguishes from simple cyst

›Free fluid signal characteristics

›Limitations

›Not first-line in acute setting

›Availability and scan time constraints

›Reserve for complex non-tubal cases

›Contraindicated in hemodynamic instability

›Cannot monitor safely in MRI

›TVUS and surgical approach preferred urgently

›CT abdomen and pelvis role

›Not first-line for suspected ectopic pregnancy

›Radiation exposure in reproductive-age females

›Lower sensitivity than TVUS for early ectopic

›Indications in ectopic workup

›Alternative diagnosis evaluation

›Appendicitis when right lower quadrant pain dominant

›Renal calculi or pyelonephritis when suspected

›Hemodynamically unstable with unclear source

›Identify free fluid distribution

›Characterize other bleeding sources

›CT findings suggestive of ectopic

›Hemoperitoneum

›Free fluid in pouch of Douglas and paracolic gutters

›High-density fluid >30 Hounsfield units suggesting blood

›Adnexal mass separate from ovary

›Ring-enhancing structure with central hypodensity

›Adjacent tubal thickening

›Guideline context

›ACEP recommends TVUS as primary imaging modality

›CT as adjunct when TVUS nondiagnostic and alternative diagnosis considered

Ultrasound

›Transvaginal ultrasound (TVUS)

›First-line and primary diagnostic modality

›Sensitivity 99% for ectopic when beta-hCG >1,500 IU/L

›Specificity 84% when beta-hCG >1,500 IU/L

›Adnexal mass with no IUP: LR+ of 111 for ectopic pregnancy

›Definitive findings

›Extrauterine gestational sac with yolk sac or embryo

›Confirms ectopic pregnancy

›Fetal cardiac activity may be visualized in viable ectopic

›Suggestive TVUS findings

›Inhomogeneous adnexal mass or tubal ring sign

›Ring of fire on Doppler around ectopic

›Empty uterus with positive beta-hCG above discriminatory zone

›Highly suspicious for ectopic or failed IUP

›Free pelvic fluid without IUP

›Suggests hemoperitoneum and possible rupture

›Point-of-care ultrasound (POCUS)

›ED bedside TVUS utility

›Identify IUP to substantially reduce ectopic probability

›Identify free fluid suggesting rupture

›ACEP Level B recommendation for POCUS in suspected ectopic

›Transabdominal POCUS supplement

›Assess for upper abdominal free fluid if rupture suspected

›Morison's pouch and splenorenal views

›Limitations

›Absence of IUP on POCUS does not confirm ectopic

›Formal radiology TVUS required when POCUS nondiagnostic

›Operator skill dependent

07Disposition/dispo39

Emergency surgical management

›Operative indications

›Hemodynamic instability

›SBP <90 mmHg or HR >110 bpm despite resuscitation

›Emergent surgical consultation and OR activation

›Ruptured ectopic with hemoperitoneum

›Free fluid on TVUS or POCUS without IUP

›Peritoneal signs on exam

›Failed medical management

›MTX failure with rising or inadequately falling beta-hCG

›Increasing pelvic pain after MTX

›Absolute contraindications to MTX

›Hepatic or renal dysfunction

›Immunodeficiency or blood dyscrasias

›Hemodynamic instability

Medical management disposition

›Outpatient MTX criteria

›Hemodynamically stable

›Normal vital signs at time of disposition

›No peritoneal signs

›TVUS criteria

›No fetal cardiac activity

›No large hemoperitoneum

›Ectopic size typically <3.5 cm (institutional protocol)

›Beta-hCG criteria

›Typically <5,000-10,000 mIU/mL per protocol

›Single-dose protocol best suited to lower levels

›Reliable follow-up

08Treatment/t86

Emergency surgical management

›Operative approach

›Laparoscopy preferred for stable patients

›Salpingectomy standard for most tubal ectopics

›Salpingostomy if contralateral tube damaged and fertility desired

›Laparotomy for hemodynamic instability

›Faster hemorrhage control

›Lower skill threshold under duress

›Intraoperative considerations

›IVF or future fertility discussion preoperative

›Specimen for histologic confirmation

Methotrexate medical management

›MTX single-dose protocol

›Dose

›50 mg/m2 IM single dose

›Body surface area calculated from weight and height

›Eligibility criteria

›Hemodynamically stable

›No fetal cardiac activity on TVUS

›Beta-hCG level within protocol threshold (typically <5,000-10,000 mIU/mL)

›No MTX contraindications

›Pre-treatment labs mandatory

›CBC, Cr, LFTs, blood type and Rh

›ACEP Level B recommendation for pre-treatment evaluation

›Absolute contraindications to MTX

›Hemodynamic instability

›Hepatic dysfunction (elevated LFTs >2x ULN)

›Renal dysfunction

›Immunodeficiency

›Active pulmonary disease (MTX pneumonitis risk)

›Peptic ulcer disease

›Blood dyscrasias

›Breastfeeding

›MTX two-dose protocol

›Indication

›Higher beta-hCG levels or larger ectopic size

›Institutional protocol variation

›Dose

›50 mg/m2 IM on day 0

›Repeat 50 mg/m2 IM on day 4 if beta-hCG falls <15% from day 0 to day 4

›Higher success rate than single-dose for larger ectopics

›Success rate approximately 87-93%

›Single-dose overall success approximately 70-88%

Post-MTX monitoring protocol

›Beta-hCG surveillance after MTX

›Day 4 beta-hCG

›Expected initial rise (days 1-4) is normal

›Do not interpret as treatment failure

›Day 7 beta-hCG

›Target: >=15% fall from day 4 level

›If fall <15%, repeat MTX or surgical evaluation

›Weekly beta-hCG thereafter

›Continue until undetectable (<5 mIU/mL)

›Resolution typically 2-8 weeks

›Return precautions

›Worsening pain, hemodynamic instability

›Syncope or shoulder pain

›These may indicate rupture despite MTX

Medications to avoid during MTX treatment

›Prohibited concurrent medications

›Folic acid supplements and prenatal vitamins

›Antagonize MTX mechanism of action

›Must be discontinued before and during treatment

›NSAIDs

›Increase MTX toxicity via reduced renal clearance

›Acetaminophen is preferred analgesic

›Alcohol

›Hepatotoxicity risk synergistic with MTX

›Avoid throughout treatment course

›Gas-forming foods and sexual activity

›Avoid until resolution to prevent confusion with rupture symptoms

Rh immunoglobulin

›Rh sensitization prevention

›Indication

›All Rh-negative patients with ectopic pregnancy

›Regardless of medical or surgical management

›Dose

›300 mcg Rh immunoglobulin IM

›Administer within 72 hours of diagnosis

›Rationale

›Prevents maternal alloimmunization

›Protects future pregnancies from hemolytic disease of newborn

Expectant management

›Criteria for expectant management

›Declining beta-hCG trend at presentation

›Spontaneous resolution possible

›Close monitoring required

›Asymptomatic PUL with falling beta-hCG

›Weekly beta-hCG until undetectable

›Return precautions mandatory

›Not appropriate if rising or plateauing beta-hCG

›Active ectopic requiring intervention

09Special Populations/sp53

Pregnancy

›Heterotopic pregnancy considerations

›Definition

›Simultaneous IUP and ectopic pregnancy

›Spontaneous rate ~1/30,000; ART rate ~1/100

›Diagnostic challenge

›IUP on TVUS does not exclude coexisting ectopic in ART patients

›Adnexal mass must still be evaluated even with confirmed IUP

›Management principles

›Surgical management of ectopic component

›MTX contraindicated due to teratogenicity to coexisting IUP

›Fetal and maternal monitoring

›Serial fetal cardiac assessment post-procedure

›Threatened miscarriage risk after surgical intervention

›Early pregnancy hormonal considerations

›Progesterone supplementation not used in ectopic management

›Progesterone delays diagnosis by maintaining ectopic

›Differentiate from threatened miscarriage where progesterone may have role

›Symptoms of pregnancy continue with ectopic

›Nausea and breast tenderness mislead patients

›May mask or delay recognition of deterioration

Geriatric

›Older reproductive age considerations

›Risk profile

›Age >35 years as independent ectopic risk factor

›Cumulative STI and tubal damage exposure

›Perimenopause may delay recognition of amenorrhea

›Pregnancy test threshold

10Background/b62

Epidemiology

›Incidence and burden

›Frequency

›1-2% of all pregnancies are ectopic

›Approximately 100,000 cases annually in the United States

›Mortality

›Accounts for 2.7% of pregnancy-related deaths overall

›Responsible for 6% of maternal deaths in early pregnancy

›Misdiagnosis rate

›Approximately 40% of ectopic pregnancies misdiagnosed at initial visit

›High index of suspicion essential in all pregnant patients

›Location distribution

›>90% are tubal ectopics

›Ampullary segment most common (70%)

›Isthmic (12%), fimbrial (11%), interstitial (2-3%)

›Non-tubal sites: ovarian, abdominal, cervical, caesarean scar ectopic

Pathophysiology

›Mechanism of ectopic implantation

›Tubal transport failure

›Damaged ciliated epithelium from PID or surgery

›Impaired peristalsis from cigarette smoking

›Adhesions altering tubal anatomy

›Fertilized ovum entrapment

›Implants in tubal wall before reaching uterine cavity

›Trophoblastic invasion of muscularis

›Invades adjacent blood vessels causing hemorrhage

›Rupture mechanism

›Expanding gestational sac causes tubal distension

11Patient Discharge Instructions/pdi36

copy discharge instructions

›What to watch for and return immediately

›Return to the emergency department immediately if

›Sudden worsening abdominal or pelvic pain

›Fainting or near-fainting

›Shoulder or neck pain (may mean internal bleeding)

›Heavy vaginal bleeding soaking more than one pad per hour

›Feeling very dizzy, weak, or unable to stand

›Rapid heartbeat or chest pain

›After methotrexate injection

›Avoid

›Folic acid vitamins and prenatal vitamins until your doctor says it is safe

›NSAIDs such as ibuprofen and naproxen — use acetaminophen instead for pain

›Alcohol during and after treatment until resolution

›Sexual intercourse until your doctor confirms resolution

›Sun exposure as methotrexate increases sun sensitivity

›Some pain and cramping in the first few days after injection is common

›This is called the separation pain

›Mild-to-moderate pain normal in days 3-7

›Severe or worsening pain after day 1 needs emergency evaluation

›Blood tests are required to confirm the medication is working

›Return for beta-hCG blood test on day 4

›Return for beta-hCG blood test on day 7

›Your levels may rise initially before falling — this is expected

›Follow-up plan

›Blood test appointments booked before leaving the department

›Day 4 and day 7 post-MTX beta-hCG

›Weekly thereafter until undetectable

12References/r25

Guidelines and key sources

›Society and clinical guideline sources

›ACOG Practice Bulletin on Ectopic Pregnancy

›Recommendations on diagnosis, MTX dosing, and surgical criteria

›ACEP Level A recommendation for MTX in stable unruptured ectopic

›Society for Academic Emergency Medicine (SAEM) ectopic pregnancy position statement

›POCUS role in ED evaluation ACEP Level B

›Serial beta-hCG in pregnancy of unknown location ACEP Level B

›Royal College of Obstetricians and Gynaecologists (RCOG) Green-top Guideline 21

›Tubal ectopic pregnancy management standards

›Laparoscopic salpingectomy as first-line surgical approach

›Key evidence

›ESEP trial (Randomized Trial of Salpingectomy vs Salpingostomy)

›No significant difference in fertility outcomes at 36 months

›Persistent trophoblast higher in salpingostomy arm

›Serial beta-hCG and TVUS discriminatory zone evidence

›Barnhart et al. studies defining rise thresholds 49-53% per 48 hours

›TVUS sensitivity 99% specificity 84% when beta-hCG >1,500 IU/L

›MTX single-dose efficacy data

›Overall success 70-88% dependent on initial beta-hCG level

›Success >90% when initial beta-hCG <1,000 mIU/mL

›Coding standards

›ICD-10 O00.10 tubal ectopic pregnancy without intrauterine pregnancy

›ICD-10 O00.00 abdominal ectopic pregnancy without intrauterine pregnancy

›ICD-10 O00.20 ovarian ectopic pregnancy without intrauterine pregnancy

›SNOMED CT 79586000 tubal pregnancy

Learn More: Ectopic Pregnancy (Unruptured)→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.